Skip to main content


  • Poster presentation
  • Open Access

Prime-boost strategy for vaccine development against both Plasmodium vivax and P. falciparum using MSP-119 as antigen

  • 1,
  • 1 and
  • 1
Malaria Journal20109 (Suppl 2) :P64

  • Published:


  • Malaria
  • Plasmodium
  • Protective Immunity
  • Vaccine Development
  • Substantial Level


Both antibodies and effector T cells appear to play important roles in the protection against P. vivax and P. falciparum infection. However, the partial protective immunity induced by vaccination with recombinant C-terminal region of merozoite surface protein (MSP-119) is mediated largely by antibodies ([1, 2]). Therefore, the objective of the present study was to evaluate, when PvMSP-119 and PfMSP-119 antigens were administered as combination at a single site in mice by using different immunization strategies (DNA/DNA, DNA/rprotein, rprotein/rprotein). We found that mice immunized with both recombinant antigens alone and in combination using heterologous prime-boost strategies (prime with DNA 100 ng and boost with recombinant protein 35 μg) lead to induced substantial levels of MSP-119 specif c IgG1, IgG2a and IgG2b (a mixed Th1/Th2 type) antibodies as measured by ELISA (Figure 1). In addition, both antigens significantly increased IFNγ responses in mice immunized with both antigens in combination using prime-boost strategy (Figure 2). rPfMSP-119 when combined with rPvMSP-119 was not affects antibodies or IFNγ and IL-10 responses in prime-boost strategy.
Figure 1
Figure 1

(abstract P64). Antibody responses to rPvMSP-119(a) and rPfMSP-119(b) in immunized mice.

Figure 2
Figure 2

(abstract P64). IFNγ responses to rPvMSP-119(a) and rPfMSP-119(b) in immunized mice.


The present results are encouraging to develop a multispecies human malaria vaccine against asexual blood stage of P. vivax and P. falciparum. Further study is needed to evaluate the protective efficacy of this vaccine in non-human primates.

Authors’ Affiliations

Malaria and Vector Research Group (MVRG), Biotechnology Research Center, Institut Pasteur, Iran, Tehran, P.O.BOX 1316943551, Iran


  1. Daly TM, Long CA: Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol. 1995, 155: 236-243.PubMedGoogle Scholar
  2. Near KA, Stowers AW, Jankovic D, Kaslow DC: Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminium hydroxide gel in a murine malaria vaccine model. Infect Immun. 2002, 70: 692-701. 10.1128/IAI.70.2.692-701.2002.PubMed CentralView ArticlePubMedGoogle Scholar


© Mehrizi et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.